Protagonist Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (18)

Latest Posts

About This Stock More About This Stock
Spectrum (SPPI) Earnings And Sales Beat Estimates In Q1
Article By: Zacks Investment Research
Saturday, May 5, 2018 9:05 PM EST
Spectrum Pharma’s shares have underperformed the industry so far this year. The stock has lost 16.5% against the industry’s decline of 5%. Plus more news on Amgen, Ligand Pharmaceuticals and Protagonist Therapeutics.
In this article: SPPI, AMGN, LGND, PTGX
Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Abandoning Phase 2 Trial Of Lead Drug
Article By: TickerTV
Thursday, March 29, 2018 11:33 AM EST
Shares of Protagonist Therapeutics dropped 54% in after-hours trading on Tuesday after announcing it would discontinue phase 2b Propel trial.
In this article: PTGX
5 Breakout Stocks Generating Exceptional Returns
Article By: Swarup Gupta
Friday, December 15, 2017 11:43 AM EST
Picking breakout stocks is probably one of the most popular techniques used by active investors. The logic behind this kind of stock selection is to determine stocks that are trading within a narrow channel.
In this article: NUAN, UEPS, TLYS, PTGX, LPG
Protagonist Therapeutics, Inc. Shares Soared After Company Announced Agreement With Janssen For PTG-200
Article By: TickerTV
Wednesday, May 31, 2017 10:54 AM EST
Protagonist Therapeutics, Inc., yesterday before the market opened announced a worldwide agreement with Janssen Biotech Inc. This made the stock to close trading yesterday at $11.82.
In this article: PTGX
Five Biotech IPOs Lead The Way In 2016
Article By: Don Dion
Friday, November 25, 2016 10:33 AM EST
While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio.
In this article: BLUE, AVXS, RETA, PTGX, CLSD

Latest Tweets for $PTGX

No tweets yet!